Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVITA Medical, Inc.RCEL · Entity 5905 | Chief Operating Officer | July 01, 2022 | July 06, 2022 |
| Zosano Pharma CorpZSAN · Entity 12518 | Director | May 24, 2021 | May 25, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVITA Medical, Inc.
Report date July 01, 2022 · Filed July 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,450 |
Reported balance
After 2022-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-07-01 · Grant · Acquired 35,950 · Balance 46,450 F1: Reflects Restricted Stock Units, each representing a contingent right to be issued one share of Common Stock. These Restricted Stock Units vest in four equal annual installments beginning on August 20, 2023. F2: Includes unvested Restricted Stock Units. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.97 · Expires 2032-07-01 | Direct | 20,650 |
Reported balance
After 2022-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-07-01 · Grant · Acquired 20,650 · Balance 20,650 F3: These Stock Options vest in four equal annual installments beginning on August 20, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects Restricted Stock Units, each representing a contingent right to be issued one share of Common Stock. These Restricted Stock Units vest in four equal annual installments beginning on August 20, 2023.
F2: Includes unvested Restricted Stock Units.
F3: These Stock Options vest in four equal annual installments beginning on August 20, 2023.
Zosano Pharma Corp
Report date May 24, 2021 · Filed May 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2031-05-23 | Direct | 90,000 |
Reported balance
After 2021-05-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-24 · Grant · Acquired 90,000 · Balance 90,000 F1: The stock option will vest with respect to 25% of the total number of the underlying shares on May 24, 2022, and the remaining shares will vest in equal monthly installments over the following three-year period such that the stock option will be fully vested on May 24, 2025 |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest with respect to 25% of the total number of the underlying shares on May 24, 2022, and the remaining shares will vest in equal monthly installments over the following three-year period such that the stock option will be fully vested on May 24, 2025
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2022 Filed Jul 6, 2022 22:55 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 20,650 | $0.00 Strike: $4.97 | $0.00 |
DisclosureSEC source: 0001209191-22-041376 · doc4.xml · derivative · entry 2 McGee Kathy M. · CIK 0001835186 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,650 Underlying: Common Stock · 20,650 shares Expires 2032-07-01 F3 · derivative.exercise_date: These Stock Options vest in four equal annual installments beginning on August 20, 2023. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 22:55 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 35,950 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-041376 · doc4.xml · nonDerivative · entry 1 McGee Kathy M. · CIK 0001835186 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,450 F1 · price: Reflects Restricted Stock Units, each representing a contingent right to be issued one share of Common Stock. These Restricted Stock Units vest in four equal annual installments beginning on August 20, 2023. F2 · balance_after: Includes unvested Restricted Stock Units. Read SEC document |
| July 06, 2021 Filed Sep 7, 2021 20:05 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 6,925 | $0.00 Strike: $20.21 | $0.00 |
DisclosureSEC source: 0001209191-21-054956 · doc4.xml · derivative · entry 2 McGee Kathy M. · CIK 0001835186 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,925 Underlying: Common Stock · 6,925 shares Expires 2031-07-06 F2 · derivative.exercise_date: These Stock Options vest in four equal annual installments upon the satisfaction of certain performance-based vesting criteria with respect to the particular portion of such Stock Options. Read SEC document |
| July 06, 2021 Filed Sep 7, 2021 20:05 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 10,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-054956 · doc4.xml · nonDerivative · entry 1 McGee Kathy M. · CIK 0001835186 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 F1 · price: Reflects Restricted Stock Units, each representing a contingent right to be issued one share of Common Stock. These Restricted Stock Units vest in four equal annual installments upon the satisfaction of certain performance-vesting criteria with respect to the particular portion of Restricted Stock Units. Read SEC document |
| May 24, 2021 Filed May 25, 2021 18:29 UTC | Zosano Pharma Corp ZSAN · Entity 12518 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001567619-21-011165 · doc1.xml · derivative · entry 1 McGee Kathy M. · CIK 0001835186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-05-23 F1 · derivative.exercise_date: The stock option will vest with respect to 25% of the total number of the underlying shares on May 24, 2022, and the remaining shares will vest in equal monthly installments over the following three-year period such that the stock option will be fully vested on May 24, 2025 Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:09 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 128,000 | $0.00 Strike: $21.88 | $0.00 |
DisclosureSEC source: 0001209191-21-018525 · doc4.xml · derivative · entry 1 McGee Kathy M. · CIK 0001835186 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,000 Underlying: Common Stock · 128,000 shares Expires 2031-03-04 F1 · derivative.exercise_date: 33,000 of these Stock Options vest in four equal annual installments beginning on January 4, 2022 and the remaining 95,000 Stock Options vest based on performance-based vesting criteria. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.